Roche (RHHBY), Ascidian Team Up for RNA Exon Editing Therapeutics

Zacks06-20

Swiss pharma giant Roche Holdings RHHBY entered into a research collaboration and licensing agreement with a biotechnology company, Ascidian Therapeutics, for the discovery and development of RNA exon...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2444029914?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/2ZuhDuDie_37lq4aVERX2Q--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/4718122d03716403704541c667907c4e","is_english":true,"pubTime":"2024-06-20 01:27","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2444029914","market":"us","top_or_hot":-1,"title":"Roche (RHHBY), Ascidian Team Up for RNA Exon Editing Therapeutics","media":"Zacks","content":"<div>\n<p>Swiss pharma giant Roche Holdings RHHBY entered into a research collaboration and licensing agreement with a biotechnology company, Ascidian Therapeutics, for the discovery and development of RNA exon...</p>\n\n<a href=\"https://finance.yahoo.com/news/roche-rhhby-ascidian-team-rna-172700069.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Roche (RHHBY), Ascidian Team Up for RNA Exon Editing Therapeutics</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRoche (RHHBY), Ascidian Team Up for RNA Exon Editing Therapeutics\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-06-20 01:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/roche-rhhby-ascidian-team-rna-172700069.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Swiss pharma giant Roche Holdings RHHBY entered into a research collaboration and licensing agreement with a biotechnology company, Ascidian Therapeutics, for the discovery and development of RNA exon...</p>\n\n<a href=\"https://finance.yahoo.com/news/roche-rhhby-ascidian-team-rna-172700069.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4120","symbol_name":"环境与设施服务","start_time":0,"source_url":"https://finance.yahoo.com/news/roche-rhhby-ascidian-team-rna-172700069.html","article_id":"2444029914","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/2ZuhDuDie_37lq4aVERX2Q--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/4718122d03716403704541c667907c4e"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2444029914","pubTimestamp":1718818020,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Swiss pharma giant Roche Holdings RHHBY entered into a research collaboration and licensing agreement with a biotechnology company, Ascidian Therapeutics, for the discovery and development of RNA exon editing therapeutics targeting neurological diseases.Ascidian’s exon editing technology is designed to provide the durability of gene therapy by rewriting RNA, while sharply reducing the risks associated with direct DNA editing and gene replacement. This approach has the potential to treat patients with one dose of an RNA exon editor.Per the terms of the agreement, Roche will get exclusive, target-specific rights to Ascidian’s RNA exon editing technology for undisclosed neurological targets for an initial payment of $42 million. While Ascidian will conduct discovery and certain preclinical activities in collaboration with Roche, the latter will be responsible for certain preclinical activities and further clinical development, manufacturing and commercialization.Drugs like Vabysmo, Ocrevu","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4120":"环境与设施服务","BK4139":"生物科技","RHHBY":"罗氏控股","TISI":"Team Inc","ALXO":"ALX Oncology Holdings","BK4007":"制药","RNA":"Avidity Biosciences, Inc.","LGND":"Ligand Pharmaceuticals Inc.","NERV":"Minerva Neurosciences","LENZ":"Therapeutics","03165":"华夏欧优股对冲"},"translate_title":"罗氏(RHHBY)与Ascidian合作开发RNA外显子编辑疗法","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALXO":1,"LENZ":1,"NERV":1,"RHHBY":1,"RNA":1,"TISI":1,"LGND":0.9,"03165":0.6},"content_text":"Swiss pharma giant Roche Holdings RHHBY entered into a research collaboration and licensing agreement with a biotechnology company, Ascidian Therapeutics, for the discovery and development of RNA exon editing therapeutics targeting neurological diseases.\nAscidian’s exon editing technology is designed to provide the durability of gene therapy by rewriting RNA, while sharply reducing the risks associated with direct DNA editing and gene replacement. This approach has the potential to treat patients with one dose of an RNA exon editor.\nPer the terms of the agreement, Roche will get exclusive, target-specific rights to Ascidian’s RNA exon editing technology for undisclosed neurological targets for an initial payment of $42 million. While Ascidian will conduct discovery and certain preclinical activities in collaboration with Roche, the latter will be responsible for certain preclinical activities and further clinical development, manufacturing and commercialization.\nIn addition, Ascidian is eligible to receive up to $1.8 billion in research, clinical, and commercial milestone payments, as well as royalties on commercial sales worldwide. It also has the liberty to develop programs against other neurological targets internally or with other collaborators.\nRoche’s shares have lost 3.4% year to date against the industry’s growth of 20.4%.\nImage Source: Zacks Investment Research\nThe company is striving to expand its pipeline and diversify through strategic acquisitions and collaborations. In January 2024, Roche acquired a clinical-stage biotechnology company, Carmot Therapeutics, for $2.7 billion to foray into the lucrative obesity space.\nThe acquisition gave Roche access to Carmot’s differentiated portfolio of incretins, including CT-388, the lead asset, phase-II ready, dual GLP-1/GIP receptor agonist for the treatment of obesity in patients with and without type 2 diabetes. Roche also obtained CT-996, a once-daily oral, small molecule GLP-1 receptor agonist currently in phase-I intended to treat obesity in patients with and without type 2 diabetes, and CT-868, a phase-II, once-daily subcutaneous injectable, dual GLP-1/GIP receptor agonist intended for the treatment of type 1 diabetes patients suffering from obesity.\nRoche also entered into a strategic collaboration and licensing agreement with MOMA Therapeutics in January. With this collaboration, Roche has access to MOMA’s proprietary KnowledgeBase platform for the identification and prosecution of a certain number of novel drug targets involved in promoting cancer cell growth and survival.\nRoche has also collaborated with MediLink Therapeutics for the development of a next-generation antibody-drug conjugate candidate YL211, targeting c-Mesenchymal epithelial transition factor (c-Met) against solid tumors.\nDrugs like Vabysmo, Ocrevus, Hemlibra and Polivy fuel Roche’s top line as the company looks to fill up the dent in sales caused by a decline in COVID-19-related sales. Competition from biosimilars for established drugs like Avastin, MabThera/Rituxan and Herceptin continues to hurt sales. Approval of new drugs should bode well for Roche in this scenario.\nZacks Rank & Stocks to Consider\nRoche currently carries a Zacks Rank #4 (Sell).\nSome better-ranked stocks in the healthcare sector are Ligand Pharmaceuticals LGND, ALX Oncology Holdings ALXO and Minerva Neurosciences, Inc. NERV, each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.\nIn the past 30 days, the Zacks Consensus Estimate for Ligand’s 2024 earnings per share (EPS) has increased 15 cents to $4.71. During the same time frame, the consensus estimate for 2025 EPS has increased 70 cents to $5.90. Year to date, shares of LGND have risen 12.7%.\nLigand beat on earnings in each of the trailing four quarters, delivering an average surprise of 56.02%.\nIn the past 60 days, the Zacks Consensus Estimate for ALX Oncology’s 2024 loss per share has narrowed from $3.33 to $2.89. During the same period, the consensus estimate for 2025 loss per share has narrowed from $2.85 to $2.73.\nALX Oncology beat on earnings in two of the trailing four quarters and missed the mark in the other two, delivering an average negative surprise of 8.83%.\nIn the past 60 days, estimates for Minerva Neurosciences’ 2024 loss per share have narrowed from $3.57 to $1.89. Loss per share estimate for 2025 has narrowed from $4.54 to $3.60 during the same time frame.\nNERV’s earnings beat estimates in one of the trailing four quarters and missed the same in the other three, the average negative surprise being 54.43%. \nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nRoche Holding AG (RHHBY) : Free Stock Analysis Report\nLigand Pharmaceuticals Incorporated (LGND) : Free Stock Analysis Report\nMinerva Neurosciences, Inc (NERV) : Free Stock Analysis Report\nALX Oncology Holdings Inc. (ALXO) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.28.1","shortVersion":"4.28.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2444029914"}